Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7367 in Combination With Antitumor Drugs in Solid Tumors (Phase IB/II)
CTR20254469Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-7367 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Dec 2025; status: active.
02
Drugs
SHR-7367
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254469.